The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Real-world barriers to treatment access in T-cell lymphoma
In this video, Christina Poh, MD, City of Hope, Duarte, CA, discusses the findings of a retrospective study examining real-world barriers to treatment access in patients with T-cell lymphoma, highlighting significant disparities in access to novel therapies, treatment with brentuximab vedotin, and clinical trial participation based on insurance status and histologic subtype. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
